Alzamend Neuro Files 8-K with Financial Updates
Ticker: ALZN · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $2,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, 8-k
TL;DR
Alzamend Neuro dropped an 8-K on Oct 15th - check financials and exhibits.
AI Summary
Alzamend Neuro, Inc. filed an 8-K on October 15, 2024, reporting on financial statements and exhibits. The company, incorporated in Delaware, is involved in pharmaceutical preparations and is headquartered in Atlanta, Georgia.
Why It Matters
This filing provides essential updates on Alzamend Neuro's financial status and exhibits, which are crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- October 15, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 (address) — Business Address
- 844-722-6333 (phone_number) — Business Phone
FAQ
What specific financial statements are being reported in this 8-K filing?
The filing indicates that financial statements and exhibits are being reported, but the specific details of these statements are not provided in the provided text.
What is the primary business of Alzamend Neuro, Inc.?
Alzamend Neuro, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
When was this 8-K filing submitted?
This 8-K filing was submitted on October 15, 2024.
Where is Alzamend Neuro, Inc. headquartered?
Alzamend Neuro, Inc. is headquartered in Atlanta, Georgia, with its principal executive offices located at 3500 Lenox Rd. NE, Suite 1500.
What is the state of incorporation for Alzamend Neuro, Inc.?
Alzamend Neuro, Inc. is incorporated in Delaware.
Filing Stats: 932 words · 4 min read · ~3 pages · Grade level 13.4 · Accepted 2024-10-15 16:30:38
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value ALZN The Nasdaq Capital M
- $2,500,000 — uires a minimum stockholders' equity of $2,500,000, and was provided 180 calendar days, or
Filing Documents
- o10142408k.htm (8-K) — 27KB
- ex99_1.htm (EX-99.1) — 9KB
- alzamendlogo_sm.jpg (GRAPHIC) — 18KB
- 0001214659-24-017549.txt ( ) — 238KB
- alzn-20241015.xsd (EX-101.SCH) — 3KB
- alzn-20241015_lab.xml (EX-101.LAB) — 33KB
- alzn-20241015_pre.xml (EX-101.PRE) — 22KB
- o10142408k_htm.xml (XML) — 4KB
01 Regulation
Item 7.01 Regulation FD Disclosure As previously reported under Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing), on September 26, 2023, Alzamend Neuro, Inc. (the " Company ") was notified by the Nasdaq Stock Market, LLC (" Nasdaq ") that it did not meet the minimum market value of listed securities requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(2), or any other continued listing standard, such as the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the " Equity Rule "), which requires a minimum stockholders' equity of $2,500,000, and was provided 180 calendar days, or until March 25, 2024, to regain compliance. The Company had not regained compliance by March 25, 2024, and Nasdaq determined to delist the Company's common stock. The Company appealed the delisting determination to a Hearings Panel (the " Panel "). In May 2024, the Panel granted the Company's request to continue its listing on The Nasdaq Capital Market, subject to Alzamend demonstrating compliance, on or before September 23, 2024, with the Equity Rule and satisfying all applicable requirements for continued listing on Nasdaq. On October 14, 2024, the Company received notice from the Panel that the COmpany Company has regained compliance with the Equity Rule, determined to continue the listing of the Company's securities on Nasdaq and stated that the matter is now closed. On October 15, 2024, the Company issued a press release to announce that the Company has demonstrated compliance with the Equity Rule and regained compliance with Nasdaq listing standards. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. In accordance with General Instruction B.2 of Form 8-K, the information under this item shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits: Exhibit No. Description 99.1 Press Release dated October 15, 2024 101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALZAMEND NEURO, INC. Dated: October 15, 2024 /s/ Henry Nisser Henry Nisser Executive Vice President and General Counsel -3-